Cipla plans to launch Molnupiravir under brand name Cipmolnu
Cipla Limited announced that the company has been granted permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country.Molnupiravir is an orally administered form of a potent ribonucleoside analogue that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Cipla plans to launch Molnupiravir under the brand name Cipmolnu.For...
Cipla Limited announced that the company has been granted permission by the Drug Controller General of India (DCGI) for the launch of Molnupiravir in the country.
Molnupiravir is an orally administered form of a potent ribonucleoside analogue that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Cipla plans to launch Molnupiravir under the brand name Cipmolnu.
For more details, check out the full story on the link below:
Cipla Bags DCGI Nod For COVID-19 Oral Antiviral, All Set To Launch Cipmolnu In India`
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd